Families deserve evidence that is clear, not exaggerated. Published clinical research shows what can happen when medication is studied alongside structured lifestyle support. It does not predict what will happen for any one person, and it is not a substitute for an individualized clinical evaluation.
What the STEP TEENS study examined
STEP TEENS was a 68-week randomized clinical trial of once-weekly semaglutide in adolescents ages 12 to under 18 with obesity. Participants received lifestyle intervention throughout the study; some also received semaglutide, while others received placebo. The trial was published in the New England Journal of Medicine in 2022 [1].
This design matters. The findings describe outcomes observed in a defined group during a clinical trial. They are not outcomes from a Thryvwell program, and they do not guarantee a particular result for an individual patient.
What the published results showed
16.1%
Average reduction in BMI among adolescents receiving semaglutide in STEP TEENS over 68 weeks, alongside lifestyle intervention [1].
The study also reported that 73% of adolescents receiving semaglutide achieved at least a 5% reduction in body weight, and 37% achieved at least a 20% reduction in body weight [1]. These results reflect the trial population and its protocol—not a promise of a result for any individual.
| Published STEP TEENS result | What it describes |
|---|---|
| 16.1% | Average BMI reduction among adolescents receiving semaglutide over 68 weeks [1] |
| 73% | Participants who achieved at least a 5% reduction in body weight [1] |
| 37% | Participants who achieved at least a 20% reduction in body weight [1] |
Why lifestyle support belongs in the conversation
The study did not evaluate medication as a replacement for everyday care. Participants received lifestyle intervention as part of the trial. Current pediatric guidance likewise describes medication, when clinically appropriate, as one part of comprehensive treatment—not a substitute for nutrition, movement, family support, or regular follow-up [2].
In real-world care, the details are personal. A clinician considers health history, current medications, growth and development when relevant, nutrition needs, side-effect tolerance, and a person's goals before recommending a plan.
Key Takeaway
What the study does not answer
A clinical trial cannot tell us exactly how a particular person will respond. Individual results vary, and medication is not appropriate for everyone. The study also cannot replace the safety screening, diagnosis, and shared decision-making that happen in an individual medical evaluation.
Evidence also changes over time. STEP TEENS provides published adolescent data. A separate ClinicalTrials.gov record describes the RESETTLE study in young adults ages 18 to 28; this article does not use that listing to make an outcome claim [4].
How to use research responsibly
- Use study results to ask informed questions, not to self-prescribe a plan.
- Ask which findings apply to your age group, health history, and goals.
- Discuss potential benefits, risks, side effects, and monitoring with a licensed clinician.
- Look for care that pairs medical decisions with ongoing support rather than relying on a prescription alone.
Wondering if your teen qualifies?
Check Your Child's Eligibility →References
- Weghuber D, et al. Once-Weekly Semaglutide in Adolescents with Obesity. N Engl J Med. 2022;387(24):2245-2257.
- Hampl SE, et al. Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents With Obesity. Pediatrics. 2023;151(2):e2022060640.
- U.S. Food and Drug Administration. Wegovy Prescribing Information. Accessed October 2026.
- ClinicalTrials.gov. STEP TEENS study record; RESETTLE study record. Accessed October 2026.
